Finance

Lists
Why is SGMT down ५.४५%?
Dive Deeper
SGMT:NASDAQ
Sagimet Biosciences Inc
US$ ७.५४
-५.४५%
(-०.४३) 1D
US$ ७.५३
-०.२०% (-०.०१५)
After hours
Closed: अक्टोबर १४, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGMT...
Open
US$ ७.७८
High
US$ ८.००
Low
US$ ७.५१
Mkt. cap
५३.२२ करोड
Avg. vol.
१३.७० लाख
Volume
१९.८५ लाख
52-wk high
US$ ११.४५
52-wk low
US$ ४.५०
EPS
-US$ १.२८
Beta
३.४६
Shares outstanding
७.०३ करोड
No. of employees
१६
Open
US$ ७.७८
High
US$ ८.००
Low
US$ ७.५१
Mkt. cap
५३.२२ करोड
Avg. vol.
१३.७० लाख
Volume
१९.८५ लाख
52-wk high
US$ ११.४५
52-wk low
US$ ४.५०
EPS
-US$ १.२८
Beta
३.४६
Shares outstanding
७.०३ करोड
No. of employees
१६
News stories
From web sources and news partners
Quiver Quantitative
Quiver Quantitative
·
१ दिन पहिले
$SGMT stock is down 9% today. Here's what we see in our data.
About Sagimet Biosciences Inc
CEO-
Employees१६
Founded२००६
HeadquartersSan Mateo, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Analyst ratings
Based on 12 analysts giving stock ratings to SGMT in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
1
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for SGMT in the last 3 months.
Highest
Current US$ ७.५४
US$ ५६.०० (+६४२.२१%)
Average
US$ २८.४६ (+२७७.२०%)
Lowest
US$ ७.०० (-७.२२%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
US$ २९.००
+२८४.४%
10/05/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
US$ २६.००
+२४४.६%
10/01/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
-
-
10/01/2026
Andrea Newkirk
Goldman Sachs
Sell
Maintained
US$ ७.००
-७.२%
09/30/2026
Jay Olson
Oppenheimer
Buy
Maintained
US$ ३८.००
+४०३.६%
10/01/2026
Edward Nash
Canaccord Genuity
Buy
Reiterated
US$ ५६.००
+६४२.२%
10/01/2026
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Maintained
US$ २५.१०
+२३२.७%
10/01/2026
Yun Zhong
Wedbush
Buy
Maintained
US$ २८.००
+२७१.१%
10/01/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
US$ २७.००
+२५७.९%
10/01/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
US$ २८.००
+२७१.१%
09/30/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
US$ ३१.००
+३१०.९%
09/27/2026
Eliana Merle
Barclays
Buy
Upgraded
US$ १८.००
+१३८.६%
09/09/2026
Ritu Baral
TD Cowen
Buy
Maintained
US$ २१.००
+१७८.३%
05/12/2026
Unknown Analyst
Rodman & Renshaw
Buy
Initiated
US$ २८.००
+२७१.१%
03/26/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
US$ २८.००
+२७१.१%
03/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
९७.३० लाख
६७.३४ लाख
६९.९५ लाख
१.१५ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
४६.०४ लाख
४०.३१ लाख
४७.१८ लाख
४२.८३ लाख
Operating expense
१.४३ करोड
१.०८ करोड
१.१७ करोड
१.५८ करोड
Total operating expenses
१.४३ करोड
१.०८ करोड
१.१७ करोड
१.५८ करोड
Operating income
-१.४३ करोड
-१.०८ करोड
-१.१७ करोड
-१.५८ करोड
Other non operating income
-
-
-
-
EBT including unusual items
-१.२९ करोड
-९५.६८ लाख
-१.०६ करोड
-१.४० करोड
EBT excluding unusual items
-१.२९ करोड
-९५.६८ लाख
-१.०६ करोड
-१.४० करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.२९ करोड
-९५.६८ लाख
-१.०६ करोड
-१.४० करोड
Net profit margin
-
-
-
-
Earnings per share
-०.४०
-०.२९
-०.३३
-०.२६
Interest and investment income
१४.२६ लाख
११.९७ लाख
१०.६३ लाख
१८.६५ लाख
Interest expense
-
-
-
-
Net interest expenses
१४.२६ लाख
११.९७ लाख
१०.६३ लाख
१८.६५ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू